A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities.
Zimovetz
Evelina A
EA
Senior Health Technology and Clinical Evidence Reviewer, Head of European Operations, RTI Health Solutions, Williams House, Manchester Science Park, Manchester, UK. ezimovetz@rti.org
Wilson
Koo
K
Samuel
Miny
M
Beard
Stephen M
SM
D001552:Benzazepines / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006801:Humans; D009017:Morbidity; D018722:Nicotinic Agonists / Q000191:economics* / Q000627:therapeutic use; D011810:Quinoxalines / Q000191:economics* / Q000627:therapeutic use; D012907:Smoking / Q000009:adverse effects*; D000068580:Varenicline
D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline